Survival of mice with NC carcinoma is unchanged by drugs that are thought to inhibit thromboxane synthesis or increase prostacyclin formation

Mice transplanted with NC carcinoma were treated with the thromboxane synthetase inhibitor dazmegrel (UK38485) or with nafazatrom (BAY G 6575), a compound that is reported to increase prostacyclin formation. Some experiments included the cytotoxic drugs methotrexate and melphalan. The tumours were e...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 1986-08, Vol.54 (2), p.257-263
Main Authors: Stamford, I F, Melhuish, P B, Carroll, M A, Corrigan, C J, Patel, S, Bennett, A
Format: Article
Language:English
Subjects:
6-Ketoprostaglandin F1 alpha - metabolism
Animals
Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Cancer Research
Chemotherapy
Drug Resistance
Epidemiology
Female
Imidazoles - therapeutic use
Mammary Neoplasms, Experimental - drug therapy
Mammary Neoplasms, Experimental - metabolism
Mammary Neoplasms, Experimental - mortality
Medical sciences
Mice
Molecular Medicine
Oncology
original-article
Pharmacology. Drug treatments
Prostaglandins E - metabolism
Pyrazoles - therapeutic use
Pyrazolones
Thromboxane B2 - metabolism
Thromboxane-A Synthase - antagonists & inhibitors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mice transplanted with NC carcinoma were treated with the thromboxane synthetase inhibitor dazmegrel (UK38485) or with nafazatrom (BAY G 6575), a compound that is reported to increase prostacyclin formation. Some experiments included the cytotoxic drugs methotrexate and melphalan. The tumours were excised under anaesthesia on day 14 or day 21 after transplantation, and weighed; some were extracted for prostanoids which were measured by radioimmunoassay. Mouse survival time was determined up to day 121, and cancer spread was determined by postmortem examination. The survival was increased by methotrexate and melphalan but not by the other drugs. Nafazatrom-treated mice tended to have lighter tumours. Although dazmegrel reduced the formation of thromboxane B2 during clotting of blood from normal mice, it did not affect the tumour yields of prostanoids. Nafazatrom had no effect on serum or tumour prostanoids. There were no obvious effects of the treatments on the recurrence of tumour in the excision scar, lung metastasis or spread to lymph nodes.
ISSN:0007-0920
1532-1827
DOI:10.1038/bjc.1986.171